HGH / Somatropin · Research guide

Ipamorelin peptide: HGH / Somatropin research guide

Catalogue reference · Laboratory research only

Not medical advice. Ipamorelin is sold for research. This guide does not recommend dosing, diagnosis, or therapy.

Ipamorelin is a growth-hormone secretagogue studied for pituitary signalling and pulse-like GH release patterns in animals -distinct from exogenous GH itself.

Plain-language snapshot

One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.

Ipamorelin — first selective growth hormone secretagogue with GHRH-like GH specificity and no significant ACTH, cortisol, or prolactin stimulation.

What shows up in scientific writing (general background)

Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.

“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.

Typical study contexts & reported directions

Rodent studies typically measure GH pulses and downstream IGF markers rather than long-term human outcomes.
GH-axis research is tightly regulated in medicine; the scientific interest is endocrine mechanism, not lifestyle optimisation.
Pituitary GH release patterns, receptor signalling, and metabolic readouts in compliant animal research.
Comparisons between secretagogues and exogenous GH in model organisms, focusing on endocrine biology.
Peer-reviewed preclinical work sometimes describes experiments that track whether first-in-class selective GHS-R1a agonist with GH specificity matching GHRH — no cortisol or ACTH elevation
Peer-reviewed preclinical work sometimes describes experiments that track whether does not stimulate prolactin secretion distinguishing it from hexarelin, GHRP-2, and GHRP-6
Peer-reviewed preclinical work sometimes describes experiments that track whether in vitro EC50 of 1.3 nM for pituitary GH release comparable to GHRP-6 potency
Peer-reviewed preclinical work sometimes describes experiments that track whether activates phospholipase C/IP3/calcium cascade selectively on somatotroph cells

Why HGH / Somatropin research discusses this compound

Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.

Quick takeaways

Research often compares it with other GHRP-class peptides for selectivity and side-effect profiles in models.

Themes from preclinical literature (technical)

Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.

First-in-class selective GHS-R1a agonist with GH specificity matching GHRH — no cortisol or ACTH elevation
Does not stimulate prolactin secretion distinguishing it from hexarelin, GHRP-2, and GHRP-6
In vitro EC50 of 1.3 nM for pituitary GH release comparable to GHRP-6 potency
Activates phospholipase C/IP3/calcium cascade selectively on somatotroph cells
Synergistic GH amplification when combined with GHRH analogues (CJC-1295, sermorelin)
Favorable safety profile demonstrated in phase II clinical trials at supratherapeutic doses

Typical handling notes (from our datasheet)

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.

Typical research dosing discussion (literature-style): 100–300 mcg subcutaneously · 1–3 times daily, typically pre-sleep · Terminal t½ ≈ 2 h; clearance 0.078 L/h/kg; Vd = 0.22 L/kg; Tmax (GH peak) ≈ 40 min; SC bioavailability ~95%; intranasal bioavailability ~20%; 60–80% recovered as intact peptide in urine/bile indicating moderate metabolic resistance (Gobburu et al., Pharmaceutical Research, 1999).

For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.

Frequently asked questions

What is Ipamorelin in plain language?
Ipamorelin is a research peptide we catalogue under “HGH / Somatropin.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.

Does this page give medical advice or dosing instructions for Ipamorelin?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.

Where can I see purity, variants, and pricing for Ipamorelin?
Use the “View product” button to open the canonical shop listing for Ipamorelin, where specifications and research SKU details are shown.

What about online case reports, before-and-after stories, or forum “logs” for Ipamorelin?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.

Need vial specs & pricing?

Open the shop listing for variants, purity notes, and research SKU details.

View product

Also known as: NNC 26-0161, Ipamorelin Acetate, IPA, Selective GH Secretagogue